Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Enhanced detection of circulating tumor DNA by fragment size analysis.

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaat4921. doi: 10.1126/scitranslmed.aat4921.

PMID:
30404863
2.

Calcineurin Silencing in Dictyostelium discoideum Leads to Cellular Alterations Affecting Mitochondria, Gene Expression, and Oxidative Stress Response.

Kobel-Höller K, Gley K, Jochinke J, Heider K, Fritsch VN, Nguyen HVD, Lischke T, Radek R, Baumgrass R, Mutzel R, Thewes S.

Protist. 2018 Aug;169(4):584-602. doi: 10.1016/j.protis.2018.04.004. Epub 2018 Apr 21.

PMID:
29960931
3.

The potential of volunteered geographic information to investigate peri-urbanization in the conservation zone of Mexico City.

Heider K, Lopez JMR, Scheffran J.

Environ Monit Assess. 2018 Mar 14;190(4):219. doi: 10.1007/s10661-018-6597-3.

PMID:
29541867
4.

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.

Gopalakrishnan B, Cheney C, Mani R, Mo X, Bucci D, Walker A, Klisovic R, Bhatnagar B, Walsh K, Rueter B, Waizenegger IC, Heider KH, Blum W, Vasu S, Muthusamy N.

Oncotarget. 2018 Jan 3;9(11):9706-9713. doi: 10.18632/oncotarget.23880. eCollection 2018 Feb 9.

5.

Adaptive servo-ventilation and sleep quality in treatment emergent central sleep apnea and central sleep apnea in patients with heart disease and preserved ejection fraction.

Heider K, Arzt M, Lerzer C, Kolb L, Pfeifer M, Maier LS, Gfüllner F, Malfertheiner MV.

Clin Res Cardiol. 2018 May;107(5):421-429. doi: 10.1007/s00392-018-1203-9. Epub 2018 Jan 25.

PMID:
29372314
6.

Whom are we treating with adaptive servo-ventilation? A clinical post hoc analysis.

Malfertheiner MV, Lerzer C, Kolb L, Heider K, Zeman F, Gfüllner F, Maier LS, Pfeifer M, Arzt M.

Clin Res Cardiol. 2017 Sep;106(9):702-710. doi: 10.1007/s00392-017-1112-3. Epub 2017 Apr 17.

PMID:
28417254
7.

Human and remote sensing data to investigate the frontiers of urbanization in the south of Mexico City.

Rodriguez Lopez JM, Heider K, Scheffran J.

Data Brief. 2016 Dec 29;11:5-11. doi: 10.1016/j.dib.2016.12.049. eCollection 2017 Apr.

8.

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.

Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J, Komrokji R, Djeu J, List A, Wei S.

Leukemia. 2017 Oct;31(10):2172-2180. doi: 10.1038/leu.2017.21. Epub 2017 Jan 18.

9.

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Betrian S, Ysebaert L, Heider KH, Delord JP, Fournié JJ, Quillet-Mary A.

Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106. No abstract available.

10.

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X, Groh V, Whitman SP, Konopitzky R, Kössl C, Bucci D, Lucas DM, Yu J, Caligiuri MA, Blum W, Adam PJ, Borges E, Rueter B, Heider KH, Marcucci G, Muthusamy N.

Blood. 2016 Jun 9;127(23):2879-89. doi: 10.1182/blood-2015-11-680546. Epub 2016 Mar 24.

11.

Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.

Krause G, Baki I, Kerwien S, Knödgen E, Neumann L, Göckeritz E, Landwehr T, Heider KH, Hallek M.

Br J Haematol. 2016 Jun;173(5):791-4. doi: 10.1111/bjh.13635. Epub 2015 Aug 14. No abstract available.

PMID:
26271483
12.

Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo.

Gurtner K, Hessel F, Eicheler W, Dörfler A, Zips D, Heider KH, Krause M, Baumann M.

Radiother Oncol. 2012 Mar;102(3):444-9. doi: 10.1016/j.radonc.2011.10.013. Epub 2011 Nov 17.

PMID:
22100655
13.

Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.

Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V, Kerwien S, Kuckertz M, Brinker R, Claasen J, Frenzel LP, Wendtner CM, Heider KH, Hallek M.

Leukemia. 2012 Mar;26(3):546-9. doi: 10.1038/leu.2011.233. Epub 2011 Sep 2. No abstract available.

PMID:
21886169
14.

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Küpcü Z, Jacobi A, Müller S, Hirt U, Adolf GR, Borges E.

Blood. 2011 Oct 13;118(15):4159-68. doi: 10.1182/blood-2011-04-351932. Epub 2011 Jul 27.

15.

Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.

Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ, Adolf GR.

Clin Cancer Res. 2008 Jul 15;14(14):4584-92. doi: 10.1158/1078-0432.CCR-07-5211.

16.

Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF.

Dörr W, Heider K, Spekl K.

Int J Radiat Biol. 2005 Aug;81(8):557-65.

PMID:
16298937
17.

Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer.

Koppe M, Schaijk Fv, Roos J, Leeuwen Pv, Heider KH, Kuthan H, Bleichrodt R.

Cancer Biother Radiopharm. 2004 Dec;19(6):720-9.

PMID:
15665619
18.

Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.

Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, Himmelsbach F, van Meel JC.

J Pharmacol Exp Ther. 2004 Nov;311(2):502-9. Epub 2004 Jun 15.

19.

Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes.

Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, Dekan G, Vogl S, Kubista E, Heider KH, Stratowa C, Schreiber M, Sommergruber W.

Cancer Res. 2004 Feb 1;64(3):844-56.

20.

CD44v6: a target for antibody-based cancer therapy.

Heider KH, Kuthan H, Stehle G, Munzert G.

Cancer Immunol Immunother. 2004 Jul;53(7):567-79. Epub 2004 Feb 5. Review.

PMID:
14762695
21.

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.

Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, Heider KH, Stehle G, Snow GB, van Dongen GA.

Cancer Immunol Immunother. 2003 Sep;52(9):576-82.

PMID:
14627130
22.

Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.

Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, Snow GB, Adolf GR, van Dongen GA.

Int J Cancer. 2002 May 20;99(3):396-402.

23.

Identification and characterization of 9D7, a novel human protein overexpressed in renal cell carcinoma.

Klade CS, Dohnal A, Fürst W, Sommergruber W, Heider KH, Gharwan H, Ratschek M, Adolf GR.

Int J Cancer. 2002 Jan 10;97(2):217-24. Erratum in: Int J Cancer 2002 Apr 20;98(6):956.

24.

Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.

Mizera-Nyczak E, Dyszkiewicz W, Heider KH, Zeromski J.

Tumour Biol. 2001 Jan-Feb;22(1):45-53.

PMID:
11054026
25.

Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.

Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, van Dongen GA.

Clin Cancer Res. 2000 Aug;6(8):3046-55.

26.

Polycation-based DNA complexes for tumor-targeted gene delivery in vivo.

Kircheis R, Schüller S, Brunner S, Ogris M, Heider KH, Zauner W, Wagner E.

J Gene Med. 1999 Mar-Apr;1(2):111-20.

PMID:
10738575
27.

Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.

Van Hal NL, Van Dongen GA, Ten Brink CB, Heider KH, Rech-Weichselbraun I, Snow GB, Brakenhoff RH.

Clin Cancer Res. 1999 Nov;5(11):3534-41.

29.
30.

Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse.

Beham-Schmid C, Heider KH, Hoefler G, Zatloukal K.

J Pathol. 1998 Dec;186(4):383-9.

PMID:
10209487
31.
32.

Comparison of CD44 expression in early colorectal carcinomas of the de novo and ex adenoma types.

Mueller JD, Heider KH, Oberhuber G, Mueller E, Bethke B, Stolte M, Höfler H.

Virchows Arch. 1998 Nov;433(5):407-14.

PMID:
9849854
33.

TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis.

Oft M, Heider KH, Beug H.

Curr Biol. 1998 Nov 19;8(23):1243-52.

34.

CD44 and variants in melanocytic skin neoplasms.

Schaider H, Soyer HP, Heider KH, Hofmann-Wellenhof R, Zatloukal K, Smolle J, Kerl H.

J Cutan Pathol. 1998 Apr;25(4):199-203.

PMID:
9609138
35.

Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer.

Müller W, Schneiders A, Heider KH, Meier S, Hommel G, Gabbert HE.

J Pathol. 1997 Oct;183(2):222-7.

PMID:
9390037
36.

Spontaneous malignant craniopharyngioma in an albino rat.

Pace V, Heider K, Persohn E, Schaetti P.

Vet Pathol. 1997 Mar;34(2):146-9.

PMID:
9066081
37.

Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas.

Heider KH, Sproll M, Susani S, Patzelt E, Beaumier P, Ostermann E, Ahorn H, Adolf GR.

Cancer Immunol Immunother. 1996 Dec;43(4):245-53.

PMID:
9003471
38.

Expression of CD44 isoforms in human skin cancer.

Simon JC, Heider KH, Dietrich A, Wuttig C, Schöpf E, Adolf GR, Ponta H, Herrlich P.

Eur J Cancer. 1996 Jul;32A(8):1394-400.

PMID:
8869105
39.

Expression of CD44 isoforms in human renal cell carcinomas.

Heider KH, Ratschek M, Zatloukal K, Adolf GR.

Virchows Arch. 1996 Jul;428(4-5):267-73.

PMID:
8764936
40.

Expression of CD44v6 in ulcerative colitis and Crohn's disease.

Reinisch W, Heider KH, Oberhuber G, Dejaco C, Adolf GR.

Lancet. 1996 Apr 13;347(9007):1049. No abstract available.

PMID:
8606594
41.

Expression of variant CD44 epitopes in human astrocytic brain tumors.

Eibl RH, Pietsch T, Moll J, Skroch-Angel P, Heider KH, von Ammon K, Wiestler OD, Ponta H, Kleihues P, Herrlich P.

J Neurooncol. 1995 Dec;26(3):165-70.

PMID:
8750182
42.

Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys.

Heider KH, Mulder JW, Ostermann E, Susani S, Patzelt E, Pals ST, Adolf GR.

Eur J Cancer. 1995 Dec;31A(13-14):2385-91.

PMID:
8652273
43.

CD44 isoforms in prognosis of breast cancer.

Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P.

Lancet. 1995 Aug 19;346(8973):502. No abstract available.

PMID:
7543643
44.

Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading.

Dämmrich J, Vollmers HP, Heider KH, Müller-Hermelink HK.

J Mol Med (Berl). 1995 Aug;73(8):395-401.

PMID:
8528741
45.

[The responsible performance of radio-oncological services; a comment on the paper by H.-B. Makoski in Strahlenther. Onkol. 171 (1995), 369].

Heider KM, Schneider G.

Strahlenther Onkol. 1995 Aug;171(8):484. German. No abstract available.

PMID:
7652678
46.
47.

CD44 variant exon epitopes in primary breast cancer and length of survival.

Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P.

Lancet. 1995 Mar 11;345(8950):615-9.

PMID:
7534855
48.

Spontaneous osteosarcoma of the meninges in an albino rat.

Pace V, Persohn E, Heider K.

Vet Pathol. 1995 Mar;32(2):204-7.

PMID:
7771066
49.

Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer.

Dall P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G, Kaufmann M, Herrlich P, Ponta H.

Int J Cancer. 1995 Feb 8;60(4):471-7.

PMID:
7530237
50.

Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44.

Sinn HP, Heider KH, Skroch-Angel P, von Minckwitz G, Kaufmann M, Herrlich P, Ponta H.

Breast Cancer Res Treat. 1995;36(3):307-313.

PMID:
8573713

Supplemental Content

Loading ...
Support Center